ResMed sets first-quarter earnings call for 4:30 p.m. on October 29
Key Facts
ResMed scheduled its fiscal 2027 first-quarter earnings call for October 29, 2026, from 4:30 to 5:30 p.m. Eastern time, according to the company’s investor relations calendar. The date gives investors their first quarterly update on the company’s performance in the new fiscal year, after it recorded record annual revenue in the prior year. But actual first-quarter figures were not included in the evidence available for this coverage, so revenue or earnings growth cited in the earlier draft cannot be confirmed. The company’s calendar had scheduled the call, but does not establish that it took place. RMD shares closed at $250.17 on October 28, according to EL7 data.
Fiscal 2026 results provide a baseline for comparison with the new quarter: ResMed revenue rose 10% to $5.7 billion, or 8% on a constant-currency basis, according to the company’s annual results statement. In the fourth quarter alone, revenue increased 9% to a record $1.5 billion, with 8% growth on a constant-currency basis. The figures show sales continued to grow at the end of the prior fiscal year, with reported growth rates differing from those adjusted for currency effects. Fourth-quarter diluted non-GAAP earnings per share also rose 16% to $2.95. For the full fiscal year, that measure was $11.17 per share, up 17%.
By business segment in fiscal 2026, revenue from sleep and respiratory care in the Americas grew 8%, while segment revenue in the rest of the world rose 10% on a constant-currency basis. Residential care software revenue increased 2% on a constant-currency basis over the same period, according to the annual results statement. These differences put the performance of the core business in the context of varied results across regions and software, rather than reducing it to the overall revenue figure. The company described its fourth-quarter results as reflecting continued momentum across its global business and sustained demand for its products, alongside disciplined execution of its strategy. The evidence does not detail how these factors contributed in fiscal 2027’s first quarter.
In September, management provided formal fiscal 2027 guidance, forecasting constant-currency core revenue growth of between 5% and 7%, and core earnings-per-share growth of between 12% and 14%, according to a transcript published on Investing.com. These ranges provide a benchmark for assessing the quarterly update when results are released, but do not represent actual first-quarter performance. In the same earlier outlook, management expected first-quarter gross margin to come in just below 62.0%, with improvement over the course of the year. Actual margin and its consistency with the expected trajectory will therefore be among the key elements of the update. The increases in first-quarter revenue, earnings per share and margin attributed to the earlier draft cannot be substantiated by the evidence provided.
Commenting on the close of fiscal 2026, Chief Executive Mick Farrell said the company was entering the new year drawing on its global scale while working to strengthen its digital capabilities to serve patients, caregivers and customers. The company tied its plan for the following year to developing those capabilities and using its product portfolio to improve patient outcomes and reduce healthcare costs. This digital focus adds a strategic dimension alongside growth in its sleep and respiratory devices and software businesses, but by itself provides no quantitative measure of its financial impact. The company also said demand for its products remained sustained in the fourth quarter. The available evidence contains no similar comment from Farrell on first-quarter performance, so the quote remains limited to the context of the prior fiscal year.
According to the company’s announcement of the results call, a webcast replay was to be available on its investor relations website about two hours after the call ended, while a telephone replay was scheduled to be available after about three hours. The company set November 12, 2026, as the date the telephone replay would expire. The replays give investors a way to review the call after its scheduled time, while the release of detailed results remains necessary to compare actual performance with fiscal-year guidance. In the meantime, the latest price documented in the provided data is the stock’s close at $250.17 on October 28, with no timing relationship to the results release specified in that data.